News | ECG | April 27, 2018

HeartSciences MyoVista ECG Device Shows Promise in Detecting Abnormal Cardiac Function

Device uses continuous wavelet transform signal processing and artificial intelligence to predict left ventricular diastolic dysfunction

HeartSciences MyoVista ECG Device Shows Promise in Detecting Abnormal Cardiac Function

April 27, 2018 — HeartSciences announced the results of a clinical study of its electrocardiography device that applies continuous wavelet transform signal processing and artificial intelligence. The study was serially conducted at The Icahn School of Medicine, Mount Sinai Hospital, New York, N.Y., and the West Virginia University (WVU) Heart and Vascular Institute, Morgantown, W. Va. The results were published online and in the April 17, 2018 issue of Journal of the American College of Cardiology (JACC).

The article titled “Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG” presents the results from the investigator-initiated clinical study that focused on evaluating the feasibility of MyoVista Wavelet ECG (wavECG) as a diagnostic tool for predicting myocardial relaxation abnormalities. Abnormal relaxation is an early feature of many types of heart disease and a key characteristic of left ventricular diastolic dysfunction (LVDD). It is typically detected using echocardiographic imaging. LVDD is a strong predictor of cardiovascular and all-cause mortality.1 Ischemia, hypertension, diabetes, valvular disease and reduced systolic function are all associated with LVDD.1, 2

Results from the feasibility study demonstrate MyoVista patented technology can detect myocardial relaxation abnormalities associated with LVDD. The study results demonstrated 80 percent sensitivity and 84 percent specificity, with an area under the curve of 91 percent for the prediction of low (e’), an echocardiographic parameter widely used in determination of LVDD. Prediction of low (e’) also correctly identified 23 out of 28 study subjects (82 percent) with significant underlying coronary artery disease. Additionally, MyoVista wavECG prediction of relaxation abnormalities also allowed recognition of subjects with more advanced stages of DD and concurrent CAD with significantly more incremental value compared with clinical variables and conventional ECG information.

The feasibility study was performed using machine learning analysis often described as artificial intelligence (AI). The study included a limited number of patients as well as other limitations, and future studies were recommended to address these limitations.

Conclusions of the trial suggest a potential role for the MyoVista wavECG Device as a screening tool for patients at risk for LVDD that would benefit from echocardiographic evaluations.

Partho Sengupta, M.D., professor, chief of cardiology and chair of cardiac innovation, WVU Heart & Vascular Institute and principal investigator in the study, commented, “These data are extremely encouraging as they suggest a potential role of signal processed ECG in early cardiac disease detection. It is quite remarkable that MyoVista demonstrated a high diagnostic precision in detecting a state of cardiac muscle dysfunction only previously detectable using cardiac ultrasound techniques. This can eventually help in appropriate cardiac testing and reduce overall healthcare costs.”

A total of 188 subjects referred from outpatient clinics to the Icahn School of Medicine, Mount Sinai Hospital for coronary computed tomography (CT) angiography also undertook in the same visit, comprehensive two-dimensional echocardiography (including tissue Doppler) that included assessment of LVDD. Subjects with arrhythmias, unstable angina, previous cardiac surgery, a pacemaker, chest deformity, or an inability to express well-defined mitral annular velocities due to severe mitral annular calcifications were excluded. Additional analysis was conducted related to a comparison cohort that were evaluated at WVU, Heart and Vascular Institute; this further validated MyoVista wavECG healthy patient characteristics as well as age and population distribution information.

For more information: www.heartsciences.com

References

1. LV Diastolic Dysfunction and Prognosis, Dalane W. Kitzman, et al., Circulation, 2012 February 14: 125(6): 743-745. doi:10.1161.CIRCULATIONAHA.111.086843

2. Diastolic Dysfunction and Diastolic Heart Failure: Diagnostic, Prognostic and Therapeutic Aspects, Maurizio Galderisi, Cardiovascular Ultrasound, 2005, 3-9 doi:10.1186/1476-7120-3-9


Related Content

News | ECG

May 8, 2025 – AccurKardia, an innovator in ECG-based diagnostics technology, recently announced that its AccurECG ...

Home May 19, 2025
Home
News | ECG

November 21, 2023 — AccurKardia, an ECG-led diagnostics software company, announced a multi-year agreement with Lucem ...

Home November 21, 2023
Home
News | ECG

October 13, 2023 — InfoBionic, Inc. today announced that it received 510(k) clearance from the U.S. Food and Drug ...

Home October 13, 2023
Home
News | ECG

October 13, 2023 — The newly MDR-certified Cardiomatics solution is accurate, fast and easy-to-use AI-based standalone ...

Home October 13, 2023
Home
News | ECG

September 26, 2023 — Heart Test Laboratories, Inc., an AI-powered medical technology company focused on transforming ...

Home September 26, 2023
Home
News | ECG

September 6, 2023 — Vektor Medical, developer of the only technology to accurately map arrhythmias using just 12-lead ...

Home September 06, 2023
Home
News | ECG

August 15, 2023 — Clario, a healthcare research technology company that delivers leading endpoint technology solutions ...

Home August 15, 2023
Home
News | ECG

July 27, 2023 — Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence (AI)-based medical ...

Home July 27, 2023
Home
News | ECG

June 21, 2023 — Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device ...

Home June 21, 2023
Home
News | ECG

June 19, 2023 — AliveCor, a global leader in personal electrocardiogram (ECG) technology, has announced a groundbreaking ...

Home June 19, 2023
Home
Subscribe Now